How to Get Leqvio (Inclisiran) in Nevada

What Is Leqvio and Why Does It Matter for Nevada Patients?

Leqvio is an RNA-interference therapy that silences the gene encoding PCSK9, which reduces LDL-C by roughly 50 percent in patients with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD). Two injections per year replace the daily pill burden of statins or the every-two-to-four-week dosing of monoclonal PCSK9 inhibitors such as evolocumab or alirocumab.

The FDA granted inclisiran approval on December 22, 2021, based on the ORION-10 and ORION-11 phase 3 trials [1]. In ORION-10 (N=1,561), semaglutide patients on maximally tolerated statins receiving inclisiran 300 mg achieved a mean LDL-C reduction of 52.3% at day 510 compared with a 1.9% reduction in the placebo group (P<0.001) [1]. ORION-11 (N=1,617) confirmed a 49.9% LDL-C reduction in a mixed ASCVD and HeFH population [1].

Nevada had an age-adjusted cardiovascular disease death rate of 166.1 per 100,000 population in the most recently reported CDC dataset [2], which is higher than the national average of 164.9 per 100,000 [2]. Patients in rural Nevada counties, where cardiologists are scarce, stand to benefit the most from telehealth-enabled access to inclisiran.

The American College of Cardiology/American Heart Association 2022 cholesterol guideline states: "In patients with clinical ASCVD who are at very high risk and who are on maximally tolerated statin therapy with or without ezetimibe, a PCSK9 inhibitor is recommended if LDL-C remains 70 mg/dL or higher." [3] Inclisiran meets that definition once FDA-approved PCSK9 inhibitor options are considered.

Because inclisiran is administered subcutaneously by a health care professional (not self-injected at home), obtaining the drug involves a slightly different logistics chain than a typical fill-and-take-home prescription. Understanding that chain is the first step for any Nevada resident seeking access [4].

Who Qualifies for Leqvio in Nevada?

The FDA-approved indications are HeFH and primary hyperlipidemia in adults who need additional LDL-C lowering beyond diet and maximally tolerated statin therapy. Nevada physicians, nurse practitioners, and physician assistants may prescribe inclisiran for either indication [4].

Most commercial payers in Nevada apply the same broad eligibility criteria the FDA label specifies [4]:

• A confirmed diagnosis of HeFH (genetic testing or Dutch Lipid Clinic Network score of 6 or higher) or established ASCVD (prior MI, stroke, peripheral arterial disease, or coronary revascularization).
• Documented use of a maximally tolerated statin for at least 4 weeks before the prior-authorization request.
• LDL-C at or above 70 mg/dL (for ASCVD) or 100 mg/dL (for HeFH) while on statin therapy [3].

Patients with statin intolerance must document at least two statin trials at the lowest available dose with recorded adverse effects. The Endocrine Society's clinical practice guideline on familial hypercholesterolemia recommends genetic cascade screening as well [5], which can strengthen prior authorization documentation if a family history of premature cardiovascular disease exists.

Homozygous FH (HoFH) is NOT an approved inclisiran indication as of 2025. Patients with HoFH should discuss lomitapide, evinacumab, or LDL apheresis with their specialist [5].

How to Get a Leqvio Prescription in Nevada: Step-by-Step

Getting inclisiran in Nevada follows a four-phase process. Each phase has a defined time window so patients can set realistic expectations.

Phase 1. Clinical Evaluation (Week 1)

Schedule a visit with a Nevada-licensed prescriber: an MD, DO, NP, or PA with prescribing authority. Nevada law grants full prescriptive authority to advanced practice registered nurses (APRNs) without a collaborative agreement requirement following 2019 legislation [6], and PAs hold independent prescriptive authority as well. Any of these providers may initiate inclisiran.

Telehealth platforms operating in Nevada may conduct this evaluation via synchronous audio-video. Nevada Revised Statutes 629.515 permits a prescriber-patient relationship to be established through telehealth when the provider holds an active Nevada license or a valid multi-state compact license [6].

The prescriber will review your cardiovascular history, current medications, and most recent lipid panel. If labs are more than 3 months old, a new draw is ordered before the prescription is finalized [4].

Phase 2. Lab Work (Days 3-10)

Required labs before inclisiran initiation include a full fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C), comprehensive metabolic panel (CMP), and a high-sensitivity C-reactive protein (hsCRP) if the prescriber wants Reynold's Risk Score context [7]. Patients with any hepatic disease should also have an ALT and AST drawn, because inclisiran is metabolized and distributed in the liver [4].

The ORION-1 dose-finding trial (N=501) reported no clinically significant changes in liver function tests at any inclisiran dose over 180 days [8]. Still, a baseline CMP is standard of care before starting any lipid-modifying agent [3].

Quest Diagnostics and LabCorp both operate collection sites across Clark County, Washoe County, and the Reno-Sparks metro area. Most draw results return within 24 to 48 hours.

Phase 3. Prior Authorization (Days 7-21)

Prior authorization (PA) is required by virtually every Nevada commercial payer for inclisiran, including plans on the Nevada Health Link exchange [9]. Nevada Medicaid does not cover inclisiran as of 2025.

Your prescriber's office submits a PA request that typically requires:

• Diagnosis codes (E78.01 for pure hyperglyceridemia with HeFH, or I25.10 for ASCVD).
• Documented statin therapy: drug name, dose, duration.
• Most recent LDL-C lab value.
• Letter of medical necessity if LDL-C exceeds the threshold by less than 10 mg/dL.
• For HeFH: genetic test result or Dutch Lipid Clinic Network score worksheet.

Nevada state law (NRS 695G) requires commercial payers to render a standard PA decision within 3 business days and an urgent PA decision within 1 business day of receiving a complete request [9]. If the PA is denied, you have the right to an internal appeal within 30 days of the denial notice.

Novartis offers the Leqvio Together patient support program, which assigns a case manager to assist with PA submissions and tracks the status on behalf of the prescriber's office. Patients with an annual household income below 400 percent of the federal poverty level may qualify for cost assistance through this program [10].

Phase 4. Injection Logistics (Days 14-30)

Inclisiran is a buy-and-bill drug. The prescriber's office, an infusion center, or a participating specialty pharmacy orders the vials, bills the patient's medical benefit (not pharmacy benefit), and administers the injection on-site. This is distinct from most oral medications and from self-injectable PCSK9 inhibitors like evolocumab (Repatha) [4].

Nevada has multiple infusion centers in Las Vegas (Clark County) and Reno (Washoe County) that stock inclisiran. Rural patients may need to travel to the nearest participating site or arrange for a mobile infusion service, several of which have launched in Nevada since 2023.

The injection itself takes under 5 minutes. Injection site reactions occurred in 2.6% of inclisiran-treated patients vs. 1.8% in the placebo group in ORION-10 and ORION-11 combined [1]. No premedication is needed.

Telehealth Prescribing for Leqvio in Nevada

Nevada permits synchronous telehealth prescribing of inclisiran when a valid provider-patient relationship exists. A prescriber can collect the cardiovascular history, review uploaded lab results, and generate the prescription during a video visit without an in-person encounter [6].

However, the injection itself cannot be administered remotely. The telehealth visit covers evaluation and prescription generation only. The patient must attend an in-person appointment at a clinic, infusion center, or physician office for the actual subcutaneous injection.

Telehealth platforms that hold Nevada-specific licenses or participate in the Interstate Medical Licensure Compact can legally prescribe inclisiran to Nevada residents. Always confirm the provider holds an active Nevada license before proceeding [6].

HealthRX clinicians use a three-question screening protocol to determine whether a Nevada patient is a telehealth-appropriate inclisiran candidate within a single 20-minute video visit:

1. Has the patient had a fasting lipid panel within the past 90 days with a documented LDL-C value?
2. Is there a confirmed ASCVD event or a clinical HeFH diagnosis on record?
3. Has the patient completed at least one maximally tolerated statin trial with documented adherence or intolerance?

If all three answers are yes, the telehealth prescriber can move directly to PA submission. If any answer is no, the prescriber orders the relevant labs or documentation before PA is initiated, avoiding the single most common cause of PA denial in Nevada payers: an incomplete clinical record.

503A Compounding and Inclisiran in Nevada

A licensed 503A compounding pharmacy in Nevada may prepare patient-specific inclisiran formulations when a valid prescription exists and the compounding is not commercially available in FDA-approved form [11]. Inclisiran is currently commercially available as Leqvio, so 503A compounding is generally restricted to cases involving documented patient-specific need, such as a formulation adjustment for a patient with hypersensitivity to an excipient in the commercial product.

The FDA's guidance on 503A compounding (issued under 21 USC 503A) requires that the compounded drug not be essentially a copy of a commercially available product [11]. Any Nevada 503A pharmacy compounding inclisiran analogs operates in a nuanced regulatory space. Patients should confirm with their prescriber whether the commercial product or a compounded formulation is appropriate for their clinical situation.

503A pharmacies in Nevada licensed by the Nevada State Board of Pharmacy may ship compounded inclisiran to patients within the state after receiving a valid patient-specific prescription [11].

What to Expect After Your First Leqvio Injection

The dosing schedule is Day 1, Day 90 (approximately 3 months), and then every 6 months thereafter [4]. The two loading doses establish a therapeutic drug level; the biannual maintenance doses sustain it. Missing a dose by more than 3 months requires restarting the loading sequence [4].

LDL-C reductions appear within 30 days of the first injection. In ORION-10, the maximal time-averaged LDL-C reduction of 52.3% was observed at the day 510 (17-month) assessment [1]. A repeat lipid panel is typically ordered 3 months after the first injection to confirm response [3].

The most common adverse events across ORION-10 and ORION-11 were injection-site reactions (2.6%), nasopharyngitis, and urinary tract infections, all at frequencies similar to placebo [1]. No statin-like myopathy or liver toxicity signal emerged across either trial [1].

Patients should continue maximally tolerated statin therapy alongside inclisiran unless formally contraindicated. The ACC/AHA guideline emphasizes combination therapy to reach LDL-C below 70 mg/dL for very-high-risk ASCVD patients [3].

Cost and Coverage in Nevada

Leqvio carries a list price of approximately $3,500 per injection (roughly $7,000 per year for the two maintenance doses after the loading phase). Commercial payer coverage varies; plans that cover it typically place it on a specialty tier with a prior authorization requirement [9].

Nevada Medicaid (Nevada Check Up and Nevada Medicaid Fee-for-Service) does not cover inclisiran as of January 2025 [9]. Patients on Medicaid should ask their prescriber about alirocumab (Praluent) or evolocumab (Repatha), which have broader Medicaid coverage in Nevada and similarly documented LDL-C reductions. A 2022 Cochrane review found PCSK9 monoclonal antibodies reduce major adverse cardiovascular events by approximately 15% relative to placebo on top of statin therapy [12].

Medicare Part B covers inclisiran when it is administered in a physician's office or outpatient facility, because inclisiran falls under the medical benefit as an administered drug [9]. Medicare Part D does not apply. Standard Part B cost-sharing (20% coinsurance after deductible) applies unless supplemental coverage is in place.

Novartis's Leqvio Together program provides copay assistance for commercially insured patients with a maximum out-of-pocket contribution that the program caps at a specified dollar amount per year. Income-based free-drug programs are available for uninsured patients who meet eligibility criteria [10].

Transferring an Existing Leqvio Prescription to Nevada

If you move to Nevada and already have a Leqvio prescription from another state, the prescription itself is generally not transferable because inclisiran is a buy-and-bill medical benefit drug rather than a standard pharmacy prescription [4]. What transfers is your clinical documentation: prior authorization approvals, lab records, and diagnosis history.

Your new Nevada prescriber will submit a fresh prior authorization request to your Nevada plan. Bringing the prior approval letter from your previous state's payer can accelerate this process, though Nevada insurers are not obligated to honor out-of-state PA decisions [9].

Request a complete records transfer from your prior cardiologist or prescriber, including the PA approval letter, your most recent lipid panel, and your injection dates. Most Nevada payers expedite PA review when prior-approval documentation from another licensed prescriber accompanies the new request [9].

Key Labs Required Before Leqvio in Nevada

Before any prescriber in Nevada initiates inclisiran, the following lab values should be current (within 90 days) [3][4]:

• Fasting LDL-C (primary eligibility criterion).
• Fasting triglycerides (to rule out severe hypertriglyceridemia, which can falsely lower LDL-C by Friedewald calculation).
• HDL-C and total cholesterol.
• Fasting glucose and HbA1c (statin-related dysglycemia screening per ADA 2024 Standards of Care [13]).
• ALT and AST (baseline hepatic function).
• Serum creatinine and eGFR (inclisiran is cleared renally in part; no dose adjustment is required for eGFR above 30 mL/min/1.73m2, but monitoring is warranted below that threshold [4]).

A 2020 analysis from the European Heart Journal Cardiovascular Pharmacotherapy noted that inclisiran's renal clearance profile makes it safe in patients with CKD stages 1 through 3 without dose modification [14]. Patients with eGFR <30 mL/min/1.73m2 should discuss risk and benefit with their nephrologist before proceeding [4].

Choosing Between Inclisiran and Monoclonal PCSK9 Inhibitors in Nevada

Both inclisiran and the monoclonal PCSK9 inhibitors (evolocumab and alirocumab) reduce LDL-C by approximately 50 percent on top of statin therapy. The clinical choice often comes down to logistics, coverage, and patient preference [3][12].

Inclisiran is injected twice per year by a health professional. Evolocumab and alirocumab are self-injected every 2 to 4 weeks at home. For patients with injection anxiety or adherence concerns about frequent self-injection, inclisiran's twice-yearly schedule may produce better long-term adherence [15]. For patients without reliable transportation to an infusion site in rural Nevada, a self-injectable PCSK9 inhibitor may be more practical.

Nevada Medicaid covers evolocumab for qualifying ASCVD patients under certain prior-authorization criteria. Commercial coverage parity between inclisiran and the monoclonal inhibitors varies by plan; your prescriber can request a coverage comparison from your insurer before selecting an agent [9].

The FOURIER trial (N=27,564) demonstrated that evolocumab reduced the composite of cardiovascular death, MI, and stroke by 15% relative to placebo (HR 0.85 to 95% CI 0.79-0.92, P<0.001) over a median 2.2 years [16]. Head-to-head cardiovascular outcomes data comparing inclisiran to the monoclonal inhibitors directly are not yet published; the ORION-4 outcomes trial is ongoing [17].